184 related articles for article (PubMed ID: 15293980)
1. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Henke BR
J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980
[No Abstract] [Full Text] [Related]
2. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR
J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385
[TBL] [Abstract][Full Text] [Related]
3. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
Willson TM; Cobb JE; Cowan DJ; Wiethe RW; Correa ID; Prakash SR; Beck KD; Moore LB; Kliewer SA; Lehmann JM
J Med Chem; 1996 Feb; 39(3):665-8. PubMed ID: 8576907
[No Abstract] [Full Text] [Related]
4. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes.
Moller DE; Greene DA
Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854
[No Abstract] [Full Text] [Related]
5. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
Ebdrup S; Pettersson I; Rasmussen HB; Deussen HJ; Frost Jensen A; Mortensen SB; Fleckner J; Pridal L; Nygaard L; Sauerberg P
J Med Chem; 2003 Apr; 46(8):1306-17. PubMed ID: 12672231
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
Patsouris D; Müller M; Kersten S
Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
[TBL] [Abstract][Full Text] [Related]
7. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
8. Novel "second-generation" approaches for the control of type 2 diabetes.
Rotella DP
J Med Chem; 2004 Aug; 47(17):4111-2. PubMed ID: 15293978
[No Abstract] [Full Text] [Related]
9. Eigenvalue analysis of peroxisome proliferator-activated receptor gamma agonists.
Liao C; Xie A; Shi L; Zhou J; Lu X
J Chem Inf Comput Sci; 2004; 44(1):230-8. PubMed ID: 14741032
[TBL] [Abstract][Full Text] [Related]
10. (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
Koyama H; Miller DJ; Boueres JK; Desai RC; Jones AB; Berger JP; MacNaul KL; Kelly LJ; Doebber TW; Wu MS; Zhou G; Wang PR; Ippolito MC; Chao YS; Agrawal AK; Franklin R; Heck JV; Wright SD; Moller DE; Sahoo SP
J Med Chem; 2004 Jun; 47(12):3255-63. PubMed ID: 15163205
[TBL] [Abstract][Full Text] [Related]
11. New pharmacologic agents for diabetes.
Bailey CJ
Curr Diab Rep; 2001 Oct; 1(2):119-26. PubMed ID: 12643107
[TBL] [Abstract][Full Text] [Related]
12. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
13. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
[TBL] [Abstract][Full Text] [Related]
15. [Thiazolidenediones, diabetes and adipogenesis].
Moreno L; Barettino D
Med Clin (Barc); 1999 Apr; 112(12):457-8. PubMed ID: 10320960
[No Abstract] [Full Text] [Related]
16. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
17. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
Schimke K; Davis TM
Curr Opin Investig Drugs; 2007 Apr; 8(4):338-44. PubMed ID: 17458185
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.
Rosen ED; Spiegelman BM
J Clin Invest; 2000 Sep; 106(5):629-31. PubMed ID: 10974014
[No Abstract] [Full Text] [Related]
20. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
Zieleniak A; Wójcik M; Woźniak LA
Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
